Printer Friendly

Avalon Ventures and COI Pharmaceuticals establish PDI Therapeutics.

M2 EQUITYBITES-May 24, 2016-Avalon Ventures and COI Pharmaceuticals establish PDI Therapeutics


United States-based Avalon Ventures and United States-based COI Pharmaceuticals have set up a new company, PDI Therapeutics, to develop novel immune-oncology therapies, it was reported yesterday.

PDI Therapeutics will concentrate on the development of immunotherapies to enlist the body's immune system to fight cancer. It is developing antibody inhibitors to specific protein, disulphide isomerase, which in case of overexpression can help tumour cells prevent detection by the immune system's NK and T cells. The therapies are intended to expose tumour cells, allowing the immune system to identify and destroy them.

The company's inhibitors are likely to be used as a stand-alone therapy or in combination with other known immunotherapies, such as CAR-NK, that stimulate the immune system to recognise and remove solid tumours.

((Comments on this story may be sent to

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:May 24, 2016
Previous Article:TRI Pointe prices public offering of USD300m senior notes due 2021.
Next Article:Acorda Therapeutics to stop development of Plumiaz Nasal Spray.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters